skip to primary navigationskip to content
 

Who are we?

The Principal Investigators and Clinician Scientists of the Cambridge Centre for Parkinson-Plus are listed below. For further details on PIs and other team members please have a look here.

 

Principal Investigators

 

Professor Roger A. Barker

Professor Roger A. Barker, FMedSci, Professor of Clinical Neurosciences, directs a programme of research that seeks to stratify community-based cohorts of patients with Parkinson and Huntington diseases and trial experimental medicines such as stem cells and gene therapies.

Professor Patrick F. Chinnery

Professor Patrick F. Chinnery, FMedSci, Professor of Neurology, studies the role of genetics and mitochondria in inherited and sporadic neurodegenerative diseases. He has translated advances from the molecular and cell biology laboratory into patient care.

Professor Giovanna R. Mallucci

Professor Giovanna R. Mallucci, FMedSci, van Geest Professor of Clinical Neurosciences and Associate Director of the UK Dementia Research Institute at the University of Cambridge, has made fundamental mechanistic discoveries in neurodegeneration, driving new treatments for Parkinsonian syndromes and dementia now poised for clinical trials.

Professor John T. O’Brien

Professor John T. O’Brien, FMedSci, Professor of Old Age Psychiatry, leads neuroimaging and biomarker research in late life depression and dementia, which has been translated to treatment guidelines and clinical trials.

Professor James B. Rowe

Professor James B. Rowe, Professor of Cognitive Neurology, directs programmes in Parkinson-Plus disorders and dementia, to develop new translational tools, combining patient cohorts with new cognitive and imaging probes, and therapeutics. He is renowned for his expertise in Progressive Supranuclear Palsy, corticobasal syndrome, and related frontotemporal lobar degeneration syndromes.

Professor David C. Rubinsztein

Professor David C. Rubinsztein, FMedSci, FRS, Professor of Molecular Neurogenetics and Academic Lead of the Alzheimer’s Research UK Cambridge Drug Discovery Institute, focuses on autophagy and developing therapeutic strategies around this to slow neurodegeneration; his expertise promises to deliver new treatments targeting α-synuclein, a major contributor to Parkinson-Plus disorders.

Dr Caroline H. Williams-Gray

Dr Caroline H. Williams-Gray, MRC Clinician Scientist and honorary consultant neurologist in the Department of Clinical Neurosciences, studies the clinical heterogeneity of Parkinson’s disease and the role of the immune system in mediating this heterogeneity, with the ultimate goal of developing immune-based therapeutic strategies for relevant subgroups of PD patients.